At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these...

詳細記述

保存先:
書誌詳細
出版年:Br J Haematol
主要な著者: Ganzel, Chezi, Wang, Xin V., Rowe, Jacob M., Richards, Susan M., Buck, Georgina, Marks, David I., Litzow, Mark R., Paietta, Elisabeth M., Foroni, Letizia, Luger, Selina M., Willman, Cheryl L., Mullighan, Charles G., Roberts, Kathryn G., Wiernik, Peter H., Douer, Dan, Lazarus, Hillard M., Tallman, Martin S., Goldstone, Anthony H.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2020
主題:
Haematological Malignancy – Clinical
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7687130/
https://ncbi.nlm.nih.gov/pubmed/32220069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16616
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料